Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Excess of glucocorticoids, either due to disease or iatrogenic, increases bone resorption and decreases bone formation and is a leading cause of osteoporosis and bone fractures worldwide. Improved therapeutic strategies are sorely needed. We investigated whether activating Wnt/β-catenin signaling protects against the skeletal actions of glucocorticoids, using female mice lacking the Wnt/β-catenin antagonist and bone formation inhibitor Sost. Glucocorticoids decreased the mass, deteriorated the microarchitecture, and reduced the structural and material strength of bone in wild-type (WT), but not in Sost–/– mice. The high bone mass exhibited by Sost–/– mice is due to increased bone formation with unchanged resorption. However, unexpectedly, preservation of bone mass and strength in Sost–/– mice was due to prevention of glucocorticoid-induced bone resorption and not to restoration of bone formation. In WT mice, glucocorticoids increased the expression of Sost and the number of sclerostin-positive osteocytes, and altered the molecular signature of the Wnt/β-catenin pathway by decreasing the expression of genes associated with both anti-catabolism, including osteoprotegerin (OPG), and anabolism/survival, such as cyclin D1. In contrast in Sost–/– mice, glucocorticoids did not decrease OPG but still reduced cyclin D1. Thus, in the context of glucocorticoid excess, activation of Wnt/β-catenin signaling by Sost/sclerostin deficiency sustains bone integrity by opposing bone catabolism despite markedly reduced bone formation and increased apoptosis. This crosstalk between glucocorticoids and Wnt/β-catenin signaling could be exploited therapeutically to halt resorption and bone loss induced by glucocorticoids and to inhibit the exaggerated bone formation in diseases of unwanted hyperactivation of Wnt/β-catenin signaling. © 2016 American Society for Bone and Mineral Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149 · cited 1×
“Glucocorticoids, producedand releasedby theadrenalglands in response tobiological stress, regulate numerous physiological processes in awide range of tissues.((2,3)) Exaggerated production of glucocorticoids is found in patients with pituitary tumors producing adrenocorticotropin hormone (ACTH) (Cushing’s disease), or…”
BackgroundShane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147 · cited 1×
“Severe suppression of turnover by bisphosphonates can also lead to reduced toughness,((57,59,60)) the energy that bone tissue absorbs before failure, which in turn could be the cause of increased risk for low-energy atypical fractures.((61,62)) In contrast to purely antiresorptive agents, Sost deficiency confers high…”
BackgroundWNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753 · cited 2×
“Previous studies showed that these doses reproduce in the mouse the hallmarks of glucocorticoid-induced osteoporosis and are equivalent to medium and high therapeutic glucocorticoid doses in humans.((31,32)) Moreover, the C57BL/6mouse is a reliable and reproducible model for glucocorticoid-induced skeletal deteriorati…”
BackgroundCanonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Glass, D. A., Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, M. M., Long, F., McMahon, A. P., Lang, R. A., et al. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.02.017 · Cited by 1,558
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071408 · Cited by 914
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890 · cited 3×
“tion of osteoblast (and osteocyte) apoptosis by glucocorticoids.((18,20,32)) Moreover, addition of the glucocorticoid dexamethasone to cultured primary calvarial osteoblasts decreased mineral deposition in cells isolated from WT or Sost mice (Fig.”
BackgroundMethodSelf-citation
Cited by
Glucocorticoid-induced osteoporosis: an update
Compston, J. (2018) · Endocrine · doi:10.1007/s12020-018-1588-2 · Cited by 471
Role and mechanism of action of sclerostin in bone
Delgado-Calle, J., Sato, A. Y., & Bellido, T. (2017) · Bone · doi:10.1016/j.bone.2016.10.007 · Cited by 443
Self-citationThe osteocyte as a signaling cell
Delgado-Calle, J., & Bellido, T. (2022) · Physiological Reviews · doi:10.1152/physrev.00043.2020 · Cited by 261
Self-citationGlucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy
Hardy, R. S., Zhou, H., Seibel, M. J., & Cooper, M. S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00097 · Cited by 258
Involvement of the gut microbiota and barrier function in glucocorticoid-induced osteoporosis
Schepper, J. D., Collins, F., Rios-Arce, N. D., Kang, H. J., Schaefer, L., Gardinier, J. D., Raghuvanshi, R., Quinn, R. A., Britton, R., Parameswaran, N., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3947 · Cited by 199
Osteoclasts protect bone blood vessels against senescence through the angiogenin/plexin-B2 axis
Liu, X., Chai, Y., Liu, G., Su, W., Guo, Q., Lv, X., Gao, P., Yu, B., Ferbeyre, G., Cao, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22131-1 · Cited by 116
Hormonal and systemic regulation of sclerostin
Drake, M. T., & Khosla, S. (2017) · Bone · doi:10.1016/j.bone.2016.12.004 · Cited by 77
“Perhaps the most convincing evidence for an effect of glucocorticoids on stimulating sclerostin production are recent data from the Bellido laboratory showing that in mice, glucocorticoids increased the expression of sclerostin and the number of sclerostin-positive osteocytes, as well as altered the molecular signatur…”
Background
Metadata
- Authors
- Sato, A. Y., Cregor, M., Delgado-Calle, J., Condon, K. W., Allen, M. R., Peacock, M., Plotkin, L. I., & Bellido, T.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-05-10
- Volume
- 31
- Issue
- 10
- Pages
- 1791-1802
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2376677157
- Cited by
- 130
- References
- 17
- FWCI
- 16.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.